tbuckley/cabot-search huggingface dataset:
Abstract 2846: Chemerin, as a serum biomarker, promotes tumorigenesis and metastasis in oral squamous cell carcinoma
Authors: Anxun Wang
Journal: Cancer Research (2019)

Abstract Chemerin encoded by retinoic acid receptor responder 2 (RARRES2) has been found to be related with malignant tumors, but its causal role in the development of oral squamous cell carcinoma (OSCC) is largely unexplored. In the present study, clinical data showed that higher serum levels of chemerin were observed in OSCC patients compared to the healthy and significantly decreased after tumor resection, and were positively associated with advanced tumor stage and lymph node metastasis. The expression level of chemerin was positive correlated with the migration and invasion of OSCC cell lines. Recombinant chemerin dose-dependently enhanced the migration, invasion and proliferation of OSCC cells in vitro, and shRNA targeting RARRES2 inhibited chemerin expression, OSCC cells metastasis and proliferation in vitro and vivo. Additionally, Chemerin activated the Manganese superoxide dismutase (SOD2) activity and increased intracellular H2O2, led to a significant decrease of E-cadherin expression and a dramatically increasing expression of p-ERK1/2, Slug, Vimentin and N-cadherin. This study suggested that chemerin was a novel biomarker for OSCC patients. Chemerin promoted the tumorigenesis and metastasis of OSCC and would be a new therapeutic target for OSCC. Keywords: Chemerin; Oral squamous cell carcinoma; Tumorgenesis; Metastasis; SOD2 Citation Format: Anxun Wang. Chemerin, as a serum biomarker, promotes tumorigenesis and metastasis in oral squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2846.
Eating and Drinking. The alkalinity of the blood, the test of food and drink in health and disease.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nitrate therapy for congestive heart failure
Authors: J. A. Franciosa
Journal: JAMA (1978)

A randomized double-blind crossover trial included 16 patients with severe congestive heart failure who received isosorbide dinitrate or placebo for eight weeks, and then the opposite treatment for eight more weeks. All patients received their usual maintenance therapy with digitalis and diuretics. Seven morbid events occurred during 85 patient-weeks of isosorbide dinitrate therapy compared with 17 during 76 patient-weeks of placebo. Severity of congestive heart failure improved in all eight patients who received isosorbide dinitrate compared with two patients who showed improvement and five whose symptoms became worse with placebo. No significant differences in physical findings, cardiac dimensions, or resting hemodynamics were observed. Maximal exercise duration increased significantly by 2.54 minutes with isosorbide dinitrate therapy, and rose insignificantly by 1.24 minutes with placebo. This preliminary trial suggests that long-term vasodilator therapy may be clinically beneficial in congestive heart failure. (<i>JAMA</i>240:443-446, 1978)
AMA Grams
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Medical Follies. An Analysis of the Foibles of Some Healing Cults, Including Osteopathy, Homeopathy, Chiropractic, and the Electronic Reactions of Abrams, with Essays on the Antivivisectionists, Health Legislation, Physical Culture, Birth Control and Rejuvenation.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renal infarction with Gianturco wool coils. Use in the management of massive proteinuria
Authors: M. J. Wu
Journal: JAMA (1980)

A mechanical device was successfully used in therapeutic renal artery occlusion in a patient with renal amyloidosis and massive proteinuria (25 g/day). The serum albumin level increased from 1.8 to 3.4 g/dL after cessation of proteinuria. There has been no evidence of peripheral embolization, hypertension, or infection of the infarcted kidney for the past 20 months following the procedure. (<i>JAMA</i>243:2425-2426, 1980)
FATIGUE.
Authors: FREDERIC S. LEE
Journal: JAMA (1906)

It is a striking principle of biology that the activity of living substance tends to inhibit its further activity. Carried to a moderate degree, this inhibition leads to the self-preservation of the living substance—to an extreme degree, to its self-destruction. The characteristics of this inhibition, its accompanying phenomena within the organism and the causes that lead to it form the subject of the present lecture. Fatigue is a comprehensive term, comprising, in its simple form, the functional state of the organism and its constituent parts after activity. Lying on the border zone where the physiologic and the pathologic meet, it reaches far into both and obscures the division lines between them. When present in slight or moderate degree, it limits achievement, but is easily recovered from; when excessive or an accompaniment of disease, it forms a serious condition, which, if in man, the medical practitioner must meet and combat. Fatigue
NEWSPAPER MEDICINE.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 18025: Systematic Screening is Necessary to Detect Post-operative Thrombosis and Evaluate Risk in Children Undergoing Cardiac Surgery: A Prospective Observational Study
Authors: Cedric Manlhiot, Leonardo R Brandao, Helen M Holtby, V. Ben Sivarajan, Jennifer L Russell, Luc Mertens, Margaret L Rand, Collen E Gruenwald, Steven M Schwartz, Seema Mital, Lia Stenyk, Martha Rolland, Sunita O'Shea, Glen S Van Arsdell, Christopher A Caldarone, Anthony K Chan, Brian W McCrindle
Journal: Circulation (2015)

Introduction: Postoperative thrombosis in children undergoing cardiac surgery with cardiopulmonary bypass (CPB) is a frequent, under-diagnosed and clinically detrimental complication. Methods: Pediatric patients were prospectively enrolled before surgery with CPB in an observational cohort study. Children &lt;1 year old and cyanotic patients were oversampled. All subjects had serial lab assessment of hemostatic status and standardized vascular ultrasound for surveillance of post-operative thrombosis. Eligible non-enrolled patients were retrospectively reviewed as concurrent controls without study surveillance. All imaging findings underwent blinded adjudication to confirm the presence and clinical importance of identified thrombi. Results: Of 400 enrolled patients (54% males, 55% &lt;1 year, 25% cyanotic), 398 (99%) completed the study, and 339 (85%) had protocol vascular ultrasound prior to or within 1 week of hospital discharge. Post-operative thrombosis was diagnosed in 99 study patients (25%) vs. 10% of the 1,019 control patients (p&lt;0.001). Clinical evaluation alone missed 59% of all postoperative thrombi and 20% of clinically important thrombi. Multivariable factors associated with higher odds of postoperative thrombosis in study patients included 4 factors reflective of reduced heparin sensitivity and/or anticoagulation levels during CPB (Table). Postoperative thrombosis was associated with longer ICU stay (5 vs. 2 days, p=0.008), longer hospital stay (6 vs. 10 days, p&lt;0.001), increased odds of reintervention or post-operation ECMO (OR: 2.7, p=0.005) and mortality (OR: 5.9, p=0.002). Conclusions: Given the poor performance of relying on clinical suspicion for detecting post-operative thrombosis, children &lt;1 year old undergoing surgery with CPB should be systematically screened for thrombosis post-operatively. Individualization of thromboprophylaxis should consider both preoperative clinical factors and heparin sensitivity.
Great Teachers in Medicine
Authors: J. R. E.
Journal: Annals of Internal Medicine (1968)

Editorials1 November 1968Great Teachers in MedicineJ. R. E.J. R. E.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-69-5-1067 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptI am not willing that this discussion should close without mention of the value of a true teacher. Give me a log hut with only a simple bench, Mark Hopkins on one end and I on the other, and you may have all the buildings, apparatus and libraries without him.—James A. Garfield, Address to Williams' College Alumni, New York, 1871.This remark of President James Garfield, usually reduced to the aphorism: "Give me Mark Hopkins on one end of a log and the student on the other," has been used countless times in the ensuing century to emphasize the importance... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: J. R. E. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1968Volume 69, Issue 5 Page: 1067-1068 Keywords Alumni Libraries ePublished: 1 December 2008 Issue Published: 1 November 1968 PDF downloadLoading ...
TROPICAL NEURASTHENIA.
Authors: W. W. KING
Journal: JAMA (1906)

Tropical is used here in the sense of locality more than to characterize any special type of neurasthenia. My object primarily is to call attention to its frequency in warm countries, at the same time touching somewhat on the disease as I have observed it. Writers on tropical diseases make little or no mention of it. Dana, in his work on "Nervous Diseases," states that it is not infrequent in tropical regions and that it is found in the West Indies. My experience extends over six years' residence in Porto Rico, but information derived from various sources has caused me to regard this condition as one quite general to the tropics, differing in degree through peculiar local influences. From what I have been told by medical men who have resided in the Philippine Islands I judge that it is even more prevalent and more severe there than in the West
Improving the Diagnosis of Pulmonary Embolism in the Emergency Department
Journal: Annals of Internal Medicine (2001)

Summaries for Patients17 July 2001Improving the Diagnosis of Pulmonary Embolism in the Emergency DepartmentSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-2-200107170-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Blood clots that form in deep veins (deep venous thrombosis) sometimes travel to the lungs, a condition known as pulmonary embolism. Patients who survive a pulmonary embolus need treatment with blood thinners, since having another pulmonary embolus could prove fatal. Methods commonly used to detect pulmonary embolism often fail to provide a definitive diagnosis. By using information from the medical history, physical examination, electrocardiogram, and chest x-ray, a simple clinical model has recently been developed to evaluate the probability of pulmonary embolism before other tests are performed (“pretest ... Author, Article, and Disclosure InformationThe summary below is from the full report titled “Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and d-dimer.” It is in the 17 July 2001 issue of Annals of Internal Medicine (volume 135, pages 98-107). The authors are PS Wells, DR Anderson, M Rodger, I Stiell, JF Dreyer, D Barnes, M Forgie, G Kovacs, J Ward, and MJ Kovacs.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoExcluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and d-dimer Philip S. Wells , David R. Anderson , Marc Rodger , Ian Stiell , Jonathan F. Dreyer , David Barnes , Melissa Forgie , George Kovacs , John Ward , and Michael J. Kovacs Metrics 17 July 2001Volume 135, Issue 2Page: I-23KeywordsD-dimerDeep vein thrombosisEmergency departmentLungsPatientsPulmonary embolismSafetyThoraxThrombosisVeins ePublished: 17 July 2001 Issue Published: 17 July 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Non-Ampullary Sporadic Duodenal Adenomas: Time For A Consensus On Endoscopic Resection?
Authors: L Materacki, D Napier, D Tate, J Anderson
Journal: Endoscopy (2021)

Aims Sporadic duodenal adenomas (SDAs) are a rare but important finding at gastroscopy due to their malignant potential. Although endoscopic resection (ER) is generally advocated this carries significant risk related to the relatively thin, vascular and fixed duodenal wall. The lack of guidelines related to SDAs leads to variability in their management with potential implications for patient outcomes.
Error in Table
Authors: Orrin Devinsky, Philippe Ryvlin, Daniel Friedman
Journal: JAMA Neurology (2018)

Hooman Kamel, MD; Caroline D. Chung, BA; Gbambele J. Kone, BS; Ajay Gupta, MD; Nicholas A. Morris, MD; Matthew E. Fink, MD; Babak B. Navi, MD, MS
Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.
Authors: Jesús García-Donas, Laia Garrigos, Nuria Lainez, Ana Santaballa, Andres Redondo, Juan Fernando Cueva, M Jesus Rubio, Mario Prieto, Jose Antonio Lopez-Guerrero, Zaida Garcia-Casado, Enrique Grande, Eva Guerra Alia, Isabel Bover, Susana Hernando Polo, Ricardo Sanchez-escribano, Alicia Hurtado, Paloma Navarro, Juan Francisco Rodriguez-Moreno
Journal: Journal of Clinical Oncology (2017)

5577 Background: Granulosa-cell tumors (GCT) of the ovary are a rare entity characterized by presenting a punctual mutation at the FOXL2 gene 402C→G (C134W). Such mutation leads to a disregulation and overstimulation of the steroidogenic pathway and, ultimately, hormone overproduction. A prior trial by our group (GREKO I trial-GETHI 2011-03; NCT01584297) showed promising activity of ketoconazole, a CYP17 inhibitor used to control steroidogenesis in several conditions. Thus, we aimed to assess the activity of Orteronel (TAK700), a selective inhibitor of 17, 20-lyase, in GCT. Methods: An open-label phase II single arm clinical trial was designed for women with metastatic or locally advanced non-resectable GCT who harbored the somatic mutation FOXL2 402C→G (C134W) and who had not received prior treatment with any CYP17 inhibitor. Treatment consisted on Orteronel 300mg BID, given orally, continuously in a 28-day treatment cycle. The primary objective was clinical benefit rate; secondary objectives were response rate, progression free and overall survival, assessment of the impact of Orteronel in reducing hormonal overproduction and toxicity. Sample size calculation was based on a two stage Simon´s design. A power of 80% was set to differentiate between a 5% and a 25% clinical benefit rate. 20% of losses had been assumed thus 20 patients were scheduled to be enrolled. Results: Since 30/06/2014 to 11/01/2017 10 patients have been included in 9 participating institutions members of Spanish Group for Research in Orphan and Unfrequent Tumors (GETHI). Due to a low recrutiment rate the study was terminated early. Median PFS was 3 months 95%CI (0-12) with 3 patients achieving disease stabilization longer than 12 months. 2 patients remain on treatment after 16 and 14 months. Clinical benefit rate (CR + PR + SD) was 50%, 95%CI (19%-81%). Seven patients have progressed and 2 have died. Only 6 suspected unresected adverse reactions (SUSARs) have been communicated so far (chest pain, fever, febrile neutropenia, eosinophila, neutropenia and anemia). Conclusions: Orteronel achieved a significant clinical benefit in advanced GCT with an favorable toxicity profile. Clinical trial information: NCT02101684.
Environmental Agents That Have the Potential to Trigger Massive Apoptotic Neurodegeneration in the Developing Brain
Authors: John W. Olney, Nuri B. Farber, David F. Wozniak, Vesna Jevtovic-Todorovic, Chrysanthy Ikonomidou
Journal: Environmental Health Perspectives (2000)

We review recent findings pertaining to several environmental agents (ethanol, phencyclidine, ketamine, nitrous oxide, barbiturates, benzodiazepines, halothane, isoflurane, and propofol) that have the potential to delete large numbers of neurons from the developing brain by a newly discovered mechanism involving interference in the action of neurotransmitters [glutamate and y-amino butyric acid (GABA) at Nmethyl-D-aspartate (NMDA)1 and GABAA receptors during the synaptogenesis period, also known as the brain growth-spurt period.Transient interference (lasting > 4 hr) in the activity of these transmitters during the synaptogenesis period (the last trimester of pregnancy and the first several years after birth in humans) causes millions of developing neurons to commit suicide (die by apoptosis).Many of these agents are drugs of abuse (ethanol is a prime example) to which the human fetal brain may be exposed during the third trimester by drug-abusing mothers.Ethanol triggers massive apoptotic neurodegeneration in the developing brain by interfering with both the NMDA and GABAA receptor systems, and this can explain the reduced brain mass and lifelong neurobehavioral disturbances associated with intrauterine exposure of the human fetus to ethanol (fetal alcohol syndrome).Exposure of the immature brain in a medical treatment context is also of concern because many of these agents are drugs used frequently as sedatives, tranquilizers, anticonvulsants, or anesthetics in pediatric and/or obstetrical medicine.Because this is a newly discovered mechanism, further research will be required to fully ascertain the nature and degree of risk posed by exposure of the developing human brain to environmental agents that act by this mechanism.
Manuscripts Approved for JNCI, January 15 to February 15, 1960
Journal: JNCI Journal of the National Cancer Institute (1960)

Manuscripts Approved for JNCI, January 15 to February 15, 1960 Get access JNCI: Journal of the National Cancer Institute, Volume 24, Issue 3, March 1960, Page 757, https://doi.org/10.1093/jnci/24.3.757 Published: 01 March 1960